UK Life Science Industry Presses Government On Need For Continued Regulatory Alignment Post-Brexit
Executive Summary
UK industry figures have outlined the importance of continuing regulatory alignment in the life sciences area after Brexit, following the latest meeting of the UK EU Life Sciences Steering Group. The UK government may be listening, but what positions will the other 27 member states take?
You may also be interested in...
UK Industry Warns Against Post-Brexit Regulatory Divergence
The UK must maintain a competitive regulatory framework at home, and its medicines agency should play a part in influencing international regulatory policy alongside other national and global organizations, says a new report from the ABPI.
Yet Another UK Call For Views On What Brexit Means For Pharma, Regulation & Health
Another inquiry investigation into the consequences of Brexit in the life sciences area has been launched, this time by the UK House of Commons health committee. Stakeholders are asked to comment on issues like the impact on the regulation of medicines and medical devices, how to ensure continued access to medicines, and whether transitional arrangements will be needed.
‘We Want You To Stay,’ EU Agency Heads Tell UK
The role of the UK drug regulator in the EU post-Brexit will depend on the outcome of complex negotiations. It’s clear that the loss of the MHRA from the network would be keenly felt by other agencies across Europe.